Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=310 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
Phase 4 N=21 Use of High Cost Monitoring During Letrozole Ovulation Induction
Infertility
Primary: Pregnancy Success Rate — 75; 25 percentage of participants
Phase 3 N=81 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Anovulation · Oligo-ovulation · Hypothalamic-pituitary Dysfunction
Primary: Percentage of Subjects With Ovulation Mid-luteal Serum Progesterone (P4) Level of Greater Than or Equal (>=) 5 Nanogram Per Milliliter (ng/mL) or Clinical Pregnancy…
Phase 3 N=265 SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Infertility · Ovulation Induction
Primary: Percentage of Participants With Ovulation — 79.1; 82.6 percentage of participants
Phase 3 N=900 Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Pregnancy · Unexplained Infertility
Primary: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. — 9; 8; 34 number of multiples
Phase 4 N=3 Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
Infertility
Primary: Fetal Heart Activity 1 Month After Oocyte Retrieval — 0; 0 participants with fetal heart activity
Phase 4 N=30 Continuous Double Ovarian Stimulation.
Fertility Issues
Primary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes
Phase 3 N=105 Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles
Infertility
Primary: Total Fertilization Proportion (i.e. Total Competent Proportion) — 0.59; 0.65 ratio
Phase 3 N=52 A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Infertility · Ovarian Stimulation
Primary: Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) — 9.5 Metaphase II Oocytes
Phase 3 N=82 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3
N/A N=20 Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation
Mood
Primary: Follicular Cycle Total Behavioral Score for Calendar of Premenstrual Experiences (COPE) Self Assessment — 3; 5 units on a scale
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
N/A N=18 Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT
Unexplained Infertility · Polycystic Ovarian Syndrome · Anovulatory
Primary: LH Surge — 9; 9 Participants
Phase 4 N=188 Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
Infertility
Primary: Mean Fertilization Proportion (2PN/Oocytes Collected) — 0.63; 0.55 proportion of oocytes fertilized
Phase 4 N=110 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovarian Syndrome · Infertility
Primary: Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3 — 1; 0; 1; 0 Participants — p=1.000
Phase 3 N=750 Pregnancy in Polycystic Ovary Syndrome II
Pregnancy · Polycystic Ovary Syndrome
Primary: Live Birth — 72; 103 Participants — p=0.007
Phase 3 N=1,509 A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
In Vitro Fertilization
Primary: Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate) — 39.0; 38.1 Percentage of participants
Phase 3 N=397 To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)
Infertility
Primary: Number of Cumulus-oocyte-complexes Retrieved, Per Attempt — 13.3; 10.6 Number of cumulus-oocyte-complexes — p=<0.001
Phase 3 N=1,390 Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
Infertility
Primary: Percentage of Participants With a Vital Pregnancy — 23.9; 26.9 percentage of participants
Phase 4 N=71 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Ovarian Hyperstimulation Syndrome
Primary: Ongoing Pregnancy — 15; 19 participants
Phase 3 N=1,011 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women
Controlled Ovarian Simulation
Primary: Ongoing Pregnancy Rate — 31.3; 25.7 percentage of participants
Phase 2 N=10 Elagolix for Fertility Enhancement Clinical Trial
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
Phase 2 N=175 The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment
Infertility
Primary: Percentage of Oocyte Maturation — 49; 36; 76; 103 percentage of expected oocyte yield — p=<0.05
Phase 4 N=120 Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist
Infertility
Primary: MII Oocytes — 9.2; 10.3 cumulus oocyte complex
Phase 3 N=39 LutrePulse Hypogonadotropic Hypogonadism
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Phase 4 N=112 Follicular Steroid Genesis in Controlled Ovarian Stimulation
Infertility · Controlled Ovarian Hyperstimulation
Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05
Phase 2 N=520 Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Primary: Number of Fertilized Oocytes (2 Pronuclei [PN]) — 7.0; 8.7; 9.2; 6.7 2PN oocytes
Phase 3 N=176 A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
Infertility
Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes